Thursday 16 October, 2025
Objectives: Daptomycin is a cyclic lipopeptide with activity against gram-positive bacteria (e.g. Staphylococcus spp., Enterococcus spp.) [1]. This antibiotic has dose-linear pharmacokinetics and…
Read morePoster: Drug/Disease Modelling - Infection
Oral ivermectin population pharmacokinetics modeling in venous plasma in healthy study participants in Kenya in preparation of BOHEMIA cluster randomized controlled trial
Thursday 16 October, 2025
Introduction: Malaria remains a significant global public health problem although this infectious disease is preventable and treatable. Despite the large-scale…
Read moreMathematical modelling of the molecular mechanisms of interaction of tenofovir with emtricitabine against HIV
Thursday 16 October, 2025
Objectives: The two nucleoside reverse transcriptase inhibitors (NRTI) Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are used in combinationfor treatment of…
Read morePopulation pharmacokinetics of rifabutin among co-infected children on lopinavir/ritonavir-based antiretroviral therapy
Thursday 16 October, 2025
Objectives: Treatment of tuberculosis in children with HIV is challenging due to drug-drug interactions (DDI). Rifampicin, an important component of the…
Read moreA general pharmacodynamic interaction modelling approach to assess semi-mechanistic synergy of ceftazidime/avibactam and fosfomycin in time kill experiments
Thursday 16 October, 2025
Objectives: Detailed mechanistic understanding of in vitro pharmacodynamic (PD) drug interactions as provided by semi-mechanistic pharmacokinetic pharmacodynamic (PKPD) modelling is…
Read moreCefepime Population Pharmacokinetics and Target Attainment in Critically ill Patients with Estimation of Probability of Neurotoxicity
Thursday 16 October, 2025
Introduction: Cefepime is a fourth-generation cephalosporin antibiotic with a broad antibacterial spectrum[1] and exhibits time-dependent bactericidal activity like other beta-lactams[2]….
Read moreDevelopment of a physiological-based pharmacokinetic model for tegoprazan: its application to prediction of drug-drug interactions with clarithromycin
Thursday 16 October, 2025
Introductions: Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea). It exhibits its antisecretory effects by competitively…
Read moreA patient-level population pharmacokinetics meta-analysis of three posaconazole formulations in immunocompromised paediatric patients
Thursday 16 October, 2025
Introduction: Posaconazole is active against invasive Aspergillus and Candida infections [1]. Based on its use for prophylaxis against and treatment…
Read morePredicting lung exposure of intramuscular niclosamide as an antiviral agent against COVID-19 using power-law-based pharmacokinetic modeling
Thursday 16 October, 2025
Background: Niclosamide, a potent anthelmintic agent, has been found to be effective against COVID-19 in recent studies [1-3], and a…
Read moreStratified medicine approaches for the treatment of drug-susceptible tuberculosis: a novel phase 2 trial design
Thursday 16 October, 2025
Objectives: A 17-week rifapentine-moxifloxacin-based regimen has been recently shown to have noninferior efficacy to the standard 26-week regimen for the…
Read more